EVONIK HEALTH CARE - YOUR COMPETITIVE ADVANTAGE
Evonik Health Care partners with the world’s pharmaceutical companies to transform complexity into value.
Our core competencies allow us to specialize where you need us most, ensuring access to the right people, products, and capabilities to streamline your path to market and improve commercial performance.
Evonik has served as a global development partner and solutions provider to the pharmaceutical industry for more than 60 years. Our broad portfolio of products, technologies and services is leveraged by more than 1,000 life science customers worldwide, including more than 90% of the world’s top pharmaceutical companies, to support the development, scale-up and supply of their APIs, formulations and drug products. With more than 50 core competencies that extend across chemistry, biotechnology and process engineering, as well as a global network of manufacturing sites and labs, we have the size, strength and versatility to address the specific needs of even the largest or most complex projects. Discover how we can reduce risk, improve quality, accelerate time to market, optimize product performance and strengthen supply security.
EVONIK PRODUCTS AND CUSTOM SERVICES
Functional excipients for oral solid dosage forms and controlled release parenterals
- EUDRAGIT® - functional polymers for oral drug delivery of drug products with immediate, delayed, controlled or many other complex release profiles
- RESOMER® - portfolio of bioresorbable polymers for controlled and specific administration of parenteral drugs for durations of up to 18 months
A global CDMO leader for advanced drug delivery
Evonik has been one of the world's leading CDMOs for many decades, helping pharmaceutical and biotech companies to release the true value of their oral and parenteral drug products.
- Modified release oral drug delivery formulation development including GI targeting
- Feasibility, pharmacokinetic, stability and other studies including analytical services
- Advanced cGMP clinical manufacturing services for complex oral solid dosage forms
- Complex parenteral drug delivery formulation development for systemic, targeted or localized delivery
- Process development, cGMP drug manufacturing and aseptic filling of parenteral drugs
- Polymer and lipid-based delivery technologies for injectables
- Technologies for small molecules, HPAPIs, peptides, proteins, nucleic acids, synthetic vaccines, controlled substances and more
- LIPEX® extruders for liposomal parenteral drug product manufacturing
Custom API and intermediates manufacturing
- Winner of the Life Science Leader CMO Leadership Awards 2020
- Western-centered manufacturing network
- Supply APIs, HPAPIs and intermediates from grams up to the largest commercial volumes
- Core competencies across chemistry, biotechnology and engineering
- More than 1,400m³ of cGMP reactor volume across a network of FDA-inspected sites in the U.S., Europe and Asia
- Process development and upscaling
- Leader in amino acids and derivatives
A broad portfolio of advanced technologies to address the specific needs of large or complex projects
- Continuous processing
- Highly potent API
- Microbial fermentation and strain development
- PEGs and mPEGS
- Carbohydrate Chemistry
- Polymer API
- Catalysis and Biocatalysis
- Chiral Chemistry
- Cryogenic Chemistry
2 Turner Place
Piscataway, NJ 08854
Phone: (732) 981-5021
Contact: Francine Clark
Explore the unique capabilities at a Vancouver, Canada site for clinical-scale manufacture of lipid nanoparticles (LNPs).
Spray-dried dispersions, hot-melt extrusion, and solubilizing excipients are common solubility enhancement techniques, but new developments to maximize amorphous solid dispersion benefits are needed.
Review the basics of solubility enhancement and the formulation and manufacture of products that enhance solubility and common questions on the topic.
Long-acting, complex drug delivery products, particularly those based on injectable microparticles, nanoparticles, and implants, are among the most attractive parenteral products.
Dr. Jochen Becker, Global Project Manager at Evonik, discusses overcoming the challenges for pharma to become greener and synergies between green chemistry and pharma manufacturing.
An effective partner must possess the necessary unique analytical capabilities for LNP characterization and the ability to support clients from concept to commercialization.
Efficient drug production through cell culture depends on the complex interplay between the drug molecule, the cell, and the process. How can you balance cell growth and productivity?
The market for biological drugs continues to grow at an impressive pace over the past years. Explore three key trends that will underpin the sustainable growth of biopharma beyond COVID-19.
Evonik Health Care's Dr. Martin Schilling and Johns Hopkins University Professor Michael Betenbaugh discuss advances and trends in cell culture-based production of biological drugs.
Discover how mRNA technologies open the doors to a whole range of new gene therapies and the role of lipid nanoparticles (LNPs) in current and future developments.
Evonik is one of the world's top 3 CMOs for API and intermediates. The brochure offers insight into their capabilities and the technologies they use to address the specific needs of the largest and most complex synthesis problems life science companies face today.
Functional capsules improve a targeted drug delivery strategy and allow the use of more sensitive active molecules. A newly launched platform of ready-to-fill capsules is free from animal-derived products.
Key differences exist between liposomes and lipid nanoparticles (LNPs), not only in their target applications, but with their actual morphology, composition, and manufacturing process.
The selection of the right formulation is critical for the development of drug products for pediatric populations. The developmental status influences the dosage form and strength, taste or odor masking, and swallowability. Review some key factors to consider during initial formulation development.
The pandemic has highlighted vulnerabilities in the global supply chain. To reduce risk, initial steps are being taken to review how to increase local production capacities and tighten potential supply chain gaps.
About the size of a shipping container, a Modular Continuous Pilot plant features a flexible, modular configuration that can enable a wide range of reactor types within a small and cost-effective footprint.
Polymeric formulations such as intra-ocular implants designed for the precise intravitreal delivery of drug products represent one of the most promising, yet challenging, areas of pharmaceutical focus.
With the significant financial costs and clinical risks involved in bringing a new injectable drug product to market, why isn’t reformulation or repurposing being used more often to meet these challenges? This interview with Dr. Tom Tice, one of the world’s leading experts on extended release injectables and implants, reviews current and emerging areas of reformulation focus and some best practices to get your strategy right.
With the right selection of dipeptides, keto acids, special amino acids or other derivatives at hand, biopharma companies can realize substantial process improvements.
What applications are being explored for lipid nanoparticle delivery technologies? Dr. Jay Natarajan, Director of R&D, competence center for LNP technology, answers questions here.
During a company's nanomedicine development program, selecting the right drug delivery technology is key. Deciding which is most suitable for an API must be determined by a complex array of factors.
The market for oral drug products with an immediate release profile continues to move towards the development of more complex dosage forms designed to address specific functional or application requirements. While each formulation is different, customers most commonly want solutions to some combination of these five key challenges.
The engagement of a CDMO partner with a broad portfolio of cell and gene therapy delivery technologies, a strong formulation track record and manufacturing flexibility is the preferred pathway for success.
Advances in synthetic biology and genetic engineering have fueled the potential of fermentation-based manufacturing. Here we examine key trends and challenges to the approach.
Few suppliers of standard or custom PEGs and mPEGs have the necessary competencies to address quality and purity requirements or to overcome technical manufacturing challenges.
Several drug products utilizing continuous manufacturing processes have been approved by the FDA, with many others in clinical development. Review the challenges and opportunities for the use of continuous manufacturing for APIs and intermediates.
While the solubility of free L-Cysteine is high at neutral pH, the applicable concentration in basal and feed media is limited. Read more about an available solution for solubility and performance challenges.
For pharma and biotech companies focused on the development of microbiome products, it's important to develop oral dosage forms that can deliver specific formulation or application outcomes.
For many complex drug products targeting the small intestine or ileocolonic region, enteric protection on its own is insufficient to maximize absorption and enhance bioavailability.
Dr. Andreas Meudt, the global head of Exclusive Synthesis for Evonik, shares his thoughts on key growth trends for HPAPIs and why more pharma companies are outsourcing their production to contract specialists.
To meet growing market demand for the use of protein-based products that have a sustainable ecological footprint, substantial efforts are now underway to utilize microbial fermentation-based processes.
Cell culture media used in biopharma production have come a long way in recent decades. This interview discusses key solubility, stability and other challenges that many biopharma companies still face.
After more than 25 years of commercial use with almost 20 parenteral drug products, LNPs are having a breakout moment. Their potential has only become clear to many since COVID-19.
Traditional filling lines lack the necessary versatility to address the growing number of complex and personalized parenteral drug products that are now being brought to market. Evonik has recently qualified a new modular aseptic filling platform that will efficiently fill drug products in powder, liquid, suspension or combination form.
Poor solubility used to be one of the main showstoppers during the development of oral drug products. How can pharma companies minimize project risk and development costs, select the right excipients, equipment and process technologies to complement their API and dosage form, and hopefully also enable higher drug loadings and improve stability? Following are five key factors that companies should keep in mind to help ensure their path to solubility enhancement is as seamless and as low risk as possible.
Discover some of the key expectations of customers who are reviewing CMOs to support the development and upscaling of their next major project.